Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Ronald Anthony Depinho

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5625-577X; OpenAlex author ID A5008120994; NIH RePORTER profile ID 1863036. Sources: OpenAlex.

Their work

Papers
28 (first author 1, last author 10)
Trials
0
Grants
2
Labs led
1
Collaborators
111
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers, 1 grant · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers, 1 grant · 2026: 3 papers

Papers 28

  1. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  2. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  3. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Last author DOI 10.1038/s41586-026-11134-x↗
  4. Genetics and biology of pancreatic ductal adenocarcinoma. Last author DOI 10.1101/gad.351863.124↗
  5. KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-2024↗
  6. Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. Last author DOI 10.1158/2159-8290.cd-24-0489↗
  7. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Co-author DOI 10.1038/s41421-024-00720-w↗
  8. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Co-author DOI 10.1016/j.devcel.2023.07.025↗
  9. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Last author DOI 10.1038/s43018-022-00500-z↗
  10. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.01.003↗
  11. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  12. Single-cell RNA sequencing in pancreatic cancer. First author DOI 10.1038/s41575-021-00471-z↗
  13. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. Last author DOI 10.1101/gad.348787.121↗
  14. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Last author DOI 10.1158/2159-8290.cd-19-0297↗
  15. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-19-0597↗
  16. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Co-author DOI 10.1038/s41586-019-1062-1↗
  17. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Last author DOI 10.1038/nature21052↗
  18. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/nature21064↗
  19. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncomms14437↗
  20. A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. Co-author PMID 28401019↗
  21. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2016.05.063↗
  22. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-1854↗
  23. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Last author DOI 10.1016/j.cell.2014.06.003↗
  24. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗
  25. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-13-2050↗
  26. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Co-author DOI 10.1038/nature12040↗
  27. Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. Co-author DOI 10.1593/neo.13276↗
  28. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Last author DOI 10.1158/2159-8290.cd-11-0031↗

Grants 2

  1. Core C-Computational Core P01CA117969↗
  2. Exploring Collateral Lethality for Development of Cancer Therapeutics R01CA225955↗

Closest collaborators

The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 14 shared papers, 1 shared grant, 2016–2026 · strength 2.28
  2. Haoqiang Ying · 20 shared papers, 2011–2026 · strength 2.01
  3. Huamin Wang · 17 shared papers, 2014–2026 · strength 1.68
  4. Andrea Viale · 11 shared papers, 2014–2026 · strength 1.05
  5. Jason B. Fleming · 11 shared papers, 2013–2026 · strength 0.99
  6. Raghu Kalluri · 3 shared papers, 1 shared grant, 2020–2025 · strength 0.99
  7. Giulio Francesco Draetta · 10 shared papers, 2014–2026 · strength 0.88
  8. Giannicola Genovese · 9 shared papers, 2014–2026 · strength 0.87
  9. Prasenjit Dey · 7 shared papers, 2017–2026 · strength 0.81
  10. Timothy Paul Heffernan · 9 shared papers, 2014–2026 · strength 0.79
  11. Alec C. Kimmelman · 6 shared papers, 2011–2026 · strength 0.69
  12. Ya’an Kang · 7 shared papers, 2013–2026 · strength 0.67
  13. Wantong Yao · 8 shared papers, 2014–2026 · strength 0.67
  14. Jincheng Han · 3 shared papers, 2021–2025 · strength 0.60
  15. Alessandro Carugo · 7 shared papers, 2014–2026 · strength 0.59
  16. Virginia Giuliani · 5 shared papers, 2014–2026 · strength 0.49
  17. Gerald C Chu · 2 shared papers, 1 shared grant, 2011–2025 · strength 0.49
  18. Tony Gutschner · 4 shared papers, 2017–2026 · strength 0.49
  19. Ralph Weissleder · 1 shared paper, 1 shared grant, 2013–2025 · strength 0.48
  20. Sarah P. Thayer · 1 shared paper, 1 shared grant, 2011–2025 · strength 0.46
  21. Cyril Henri Benes · 1 shared grant, 2025 · strength 0.45
  22. Phillip Andrew Futreal · 1 shared grant, 2025 · strength 0.45
  23. NABEEL El-BARDEESY · 1 shared grant, 2025 · strength 0.45
  24. Lewis C. Cantley · 1 shared grant, 2025 · strength 0.45
  25. James wesley Horner · 1 shared grant, 2025 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.